NCT05392751: A trial that was reported late by Endogena Therapeutics, Inc
This trial has reported, although it was 491 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05392751 |
|---|---|
| Title | Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 2, 2022 |
| Completion date | April 24, 2024 |
| Required reporting date | April 24, 2025, midnight |
| Actual reporting date | Aug. 28, 2026 |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | 491 |